Previous 10 | Next 10 |
SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the first patient has been trea...
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, pre...
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, pres...
SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the Journal of Hepatology ha...
The FDA has granted Fast Track designation to Metacrine's(MTCR) MET642, the second farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis ((NASH)).Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing ...
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the U.S. Food & Drug Adminis...
The first patient has been treated in Metacrine's (MTCR) Phase 2a trial evaluating MET409 (50 mg) in combination with empagliflozin (Jardiance), in patients with both type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis ((NASH)). The 12-week trial will enroll up to 120 patients in...
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the first patient has been treat...
MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase Doses Selected for Phase 2a Trial in Patients with NASH; On-Track to Initiate in 1H21 SAN DIEGO, Dec. 17, 2020 (...
Gainers: SCWorx (WORX) +90%, Oramed Pharmaceuticals (ORMP) +31%, Rhythm Pharmaceuticals (RYTM) +19%, Genfit (GNFT) +15%, Verastem (VSTM) +13%.Losers: AnPac Bio-Medical Science (ANPC) -11%, Sientra (SIEN) -9%, Alphatec Holdings (ATEC)...
News, Short Squeeze, Breakout and More Instantly...
A Beginner’s Guide to Trading Penny Stocks Under $1 The stock market is a complex and ever-changing landscape. For investors looking to get in on the action, stocks trading for under $1 can present significant potential returns. But like anything else in the stock market today, there...
LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information reg...
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progre...